This free-for-members CME meets the DEA mandated 8 hours of Medication Access and Training Expansion (MATE) Act. Read more about MATE: New DEA training requirement: who has to do it, and how to get it done.
More than 48 million Americans struggle with substance use disorder, and three out of every four do not receive the treatment they need.* Chances are a portion of your patient base needs your help.
Learn the most up-to-date practices that help create a non-stigmatizing, trauma-informed approach to treatment and recovery. Put your learning to the test with new immersive technology that simulates a real patient interaction.
You’ll explore:
*National Survey on Drug Use and Health, November 2023
Alcohol Use Disorder: Screen, Diagnose, Treat and Support
Joyce Troxler, MD
Considering the Patient Perspective
Elizabeth Salisbury-Afshar, MD, MPH, FAAFP, DFASAM, FACPM; Brandon George
Emerging Psychoactive Substances: Fentanyls, Kratom, and Xylazine
Jasleen Salwan, MD, MPH
Harm Reduction and Addressing Stigma
Elizabeth Salisbury-Afshar, MD, MPH, FAAFP, DFASAM, FACPM
Harm Reduction: Any Positive Change
Elizabeth Salisbury-Afshar, MD, MPH, FAAFP, DFASAM, FACPM
Intake Assessment and Care Coordination
David O’Gurek, MD
Interpretation of Toxicology Results
Anika Alvanzo, MD, MS, DFASAM, FACP
Managing Common Comorbidities: Sleep, Anxiety, and Depression
Sky Lee, MD, AAHIVS
Principles of Motivational Interviewing
David O’Gurek, MD
Smoking Cessation and e-Cigarettes
Marie-Elizabeth Ramas, MD, FAAFP
Stimulant Use Disorder: The Tools in our Toolbox
Hannah Snyder, MD
Substance Use Disorders Edition 2 Reflection and Translation to Practice® (t2p®)
David O’Gurek, MD
The Evidence Base for Treatment of OUD
Elizabeth Salisbury-Afshar, MD, MPH, FAAFP, DFASAM, FACPM
The Impact of Drug Policy on SUDs
Elizabeth Salisbury-Afshar, MD, MPH, FAAFP, DFASAM, FACPM; David O’Gurek, MD; Jason Glenn, PhD
Trauma-Informed Care
David O’Gurek, MD
Treatment of OUD with Buprenorphine Part 1: Initiation of Treatment
Nicole Gastala, MD
Treatment of OUD with Buprenorphine Part 2: Follow-up Visits and Maintenance
Margaret Lowenstein, MD, MPhil, MSHP
What is Addiction?
Elizabeth Salisbury-Afshar, MD, MPH, FAAFP, DFASAM, FACPM
*Enhance your patient care today and earn up to 2 additional AAFP Prescribed credits for when you complete the Translation to Practice® (t2p®) process.
David O’Gurek, MD – Course Director
Speakers:
Anika Alvanzo, MD, MS, DFASAM, FACP
Brandon George
David O’Gurek, MD – Course Director
Elizabeth Salisbury-Afshar, MD, MPH, FAAFP, DFASAM, FACPM
Hannah Snyder, MD
Jasleen Salwan, MD, MPH
Jason Glenn, PhD
Joyce Troxler, MD
Margaret Lowenstein, MD, MPhil, MSHP
Marie-Elizabeth Ramas, MD, FAAFP
Nicole Gastala, MD
Sky Lee, MD, AAHIVS
Upon completion of this CME activity, you should be able to:
The AAFP has reviewed Substance Use Disorders Edition 2 and deemed it acceptable for up to 15.75 Enduring Materials, Self-Study AAFP Prescribed credit. Term of Approval is from 3/19/2024 to 3/19/2027. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
The AAFP is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
The American Academy of Family Physicians designates this Enduring Materials for a maximum of 15.75 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
CME activities approved for AAFP credit are recognized by the AOA as equivalent to AOA Category 2 credit.
Following this CME activity, participants will have the opportunity to earn an additional two Prescribed credits for participation in each Translation to Practice® exercise. Information on Translation to Practice® will be shared within the activity.